Micorrizas arbusculares de la amazonía colombiana :catálogo ilustrado

El catálogo es el resultado de un trabajo de más de tres años y más de 400 muestras revisadas, en el cual se describen aquellos morfotipos que frecuentemente aparecen en suelos de la Amazonia colombiana. Incluye además de las descripciones, mapas de distribución, plantas hospederas, coberturas asociadas, y tipos de suelo comúnmente asociados a los morfotipos, a partir del uso de información recogida en campo y que hacen parte de una base de datos que el Instituto Sinchi posee. La conjunción de todas estas variables relacionadas, pueden ser una herramienta útil para identificar correctamente un morfotipo, ampliar el conocimiento de este grupo de hongos, fomentar la investigación en el tema y promover el uso de este recurso. El catálogo es entonces un documento de consulta que pretende facilitar la labor investigativa de los interesados en estudiar esta simbiosis en la Amazonia colombiana

CARBON FIXING CAPACITY OF AMAZONIAN SOILS IN RELATION TO ITS DEGRADATION CONDITIONS

Amazonian deforestation and transformation alert about their effects worldwide. One concern is the increase of the Carbon (C) levels emitted. Previous works have estimated the fixed C in Amazon forests without including the C stored in soils. Within soil, the organic carbon molecules are highly sensitive to degradation, affecting the natural capacity of soils to fix and store C. The present study evaluates the impact of degradation in the natural capacity of Amazon soils to fix C. Thirty five farms with different typology were selected in Caquetá department which hold the highest deforestation and soil degradation rates in the Colombian Amazon. Soil samples were taken from natural forest relicts, cropping areas and introduced pastures of the farms, in locations with high, intermediate and low soil degradation. Aerial biomass was estimated in pastures with different level of soil degradation. Changes in the labile C stock were estimated from the soil organic carbon and the microbial biomass using substrate induced respiration. Results showed that the main C pool is in the natural forest relicts and the crops of the farms, independently from the size or type of farm sampled. The hills with higher intervention showed the lowest soil C fixation capacities. The soil C fixation capacity was related with changes in the soil microbial composition where conserved soils store preferentially C as fungal biomass while degraded soils store C as bacterial biomass. These estimations contribute to establish the cost of sustainability and soil degradation in the Colombian Amazon

Diversidad biológica y cultural del sur de la Amazonia colombiana

La gran cuenca amazónica compartida por Brasil, Colombia, Perú, Bolivia, Venezuela, Ecuador y las tres Guyanas, contiene una de las mayores riquezas biológicas y culturales del planeta y es considerada parte de la seguridad ecológica global. Constituye el 45% de los bosques tropicales del mundo, es una de las áreas silvestres más extensas y de mayor reserva de agua dulce del planeta, su sistema hídrico es el mayor tributario de todos los océanos, alberga aún, cerca de 379 grupos étnicos y en cuanto a endemismo, no existe otra región que se le aproxime. En Colombia, la Amazonia a lo largo de la historia ha sufrido distintos procesos de intervención antrópica: la conquista; la colonización; el auge del caucho y la quina; la explotación maderera, petrolera; la implementación de cultivos de uso ilícito y de sistemas productivos no aptos a las condiciones del medio natural; entre otros, son procesos que han socavado tanto los recursos biológicos como los culturales. Conscientes de la problemática actual de la Amazonia así como de la importancia que reviste para el mundo y para el país, la Corporación para el Desarrollo Sostenible del Sur de la Amazonia –Corpoamazonia– y el Instituto de Investigación de Recursos Biológicos Alexander von Humboldt –IAvH-, firmaron en el año 2004 un convenio con el n de aunar esfuerzos para formular el plan de acción en biodiversidad en la región sur de la Amazonia colombiana (departamentos de Caquetá, Putumayo y Amazonas). El plan de acción, busca posicionar la biodiversidad en el desarrollo regional y contribuir a un mayor conocimiento y a unas mejores prácticas de conservación y utilización sostenible de los recursos biológicos y culturales de este importante espacio geográfico. Desarrolla a escala regional, la Política Nacional en Biodiversidad y la Propuesta Técnica de Plan de Acción Nacional en Biodiversidad – Biodiversidad siglo XXI -

XX Semana de la Enseñanza de la Física

25 a 29 de septiembre de 2017Facultad de Ciencias y EducaciónProyecto Curricular de Licenciatura en FísicaUniversidad Distrital Francisco José de Calda

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Background: Additional safe and efficacious vaccines are needed to control the COVID-19 pandemic. We aimed to analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate. Methods: HERALD is a randomised, observer-blinded, placebo-controlled, phase 2b/3 clinical trial conducted in 47 centres in ten countries in Europe and Latin America. By use of an interactive web response system and stratification by country and age group (18–60 years and ≥61 years), adults with no history of virologically confirmed COVID-19 were randomly assigned (1:1) to receive intramuscularly either two 0·6 mL doses of CVnCoV containing 12 μg of mRNA or two 0·6 mL doses of 0·9% NaCl (placebo) on days 1 and 29. The primary efficacy endpoint was the occurrence of a first episode of virologically confirmed symptomatic COVID-19 of any severity and caused by any strain from 15 days after the second dose. For the primary endpoint, the trial was considered successful if the lower limit of the CI was greater than 30%. Key secondary endpoints were the occurrence of a first episode of virologically confirmed moderate-to-severe COVID-19, severe COVID-19, and COVID-19 of any severity by age group. Primary safety outcomes were solicited local and systemic adverse events within 7 days after each dose and unsolicited adverse events within 28 days after each dose in phase 2b participants, and serious adverse events and adverse events of special interest up to 1 year after the second dose in phase 2b and phase 3 participants. Here, we report data up to June 18, 2021. The study is registered at ClinicalTrials.gov, NCT04652102, and EudraCT, 2020–003998–22, and is ongoing. Findings: Between Dec 11, 2020, and April 12, 2021, 39 680 participants were enrolled and randomly assigned to receive either CVnCoV (n=19 846) or placebo (n=19 834), of whom 19 783 received at least one dose of CVnCoV and 19 746 received at least one dose of placebo. After a mean observation period of 48·2 days (SE 0·2), 83 cases of COVID-19 occurred in the CVnCoV group (n=12 851) in 1735·29 person-years and 145 cases occurred in the placebo group (n=12 211) in 1569·87 person-years, resulting in an overall vaccine efficacy against symptomatic COVID-19 of 48·2% (95·826% CI 31·0–61·4; p=0·016). Vaccine efficacy against moderate-to-severe COVID-19 was 70·7% (95% CI 42·5–86·1; CVnCoV 12 cases in 1735·29 person-years, placebo 37 cases in 1569·87 person-years). In participants aged 18–60 years, vaccine efficacy against symptomatic disease was 52·5% (95% CI 36·2–64·8; CVnCoV 71 cases in 1591·47 person-years, placebo, 136 cases in 1449·23 person-years). Too few cases occurred in participants aged 61 years or older (CVnCoV 12, placebo nine) to allow meaningful assessment of vaccine efficacy. Solicited adverse events, which were mostly systemic, were more common in CVnCoV recipients (1933 [96·5%] of 2003) than in placebo recipients (1344 [67·9%] of 1978), with 542 (27·1%) CVnCoV recipients and 61 (3·1%) placebo recipients reporting grade 3 solicited adverse events. The most frequently reported local reaction after any dose in the CVnCoV group was injection-site pain (1678 [83·6%] of 2007), with 22 grade 3 reactions, and the most frequently reported systematic reactions were fatigue (1603 [80·0%] of 2003) and headache (1541 [76·9%] of 2003). 82 (0·4%) of 19 783 CVnCoV recipients reported 100 serious adverse events and 66 (0·3%) of 19 746 placebo recipients reported 76 serious adverse events. Eight serious adverse events in five CVnCoV recipients and two serious adverse events in two placebo recipients were considered vaccination-related. None of the fatal serious adverse events reported (eight in the CVnCoV group and six in the placebo group) were considered to be related to study vaccination. Adverse events of special interest were reported for 38 (0·2%) participants in the CVnCoV group and 31 (0·2%) participants in the placebo group. These events were considered to be related to the trial vaccine for 14 (<0·1%) participants in the CVnCoV group and for five (<0·1%) participants in the placebo group. Interpretation: CVnCoV was efficacious in the prevention of COVID-19 of any severity and had an acceptable safety profile. Taking into account the changing environment, including the emergence of SARS-CoV-2 variants, and timelines for further development, the decision has been made to cease activities on the CVnCoV candidate and to focus efforts on the development of next-generation vaccine candidates. Funding: German Federal Ministry of Education and Research and CureVac